Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Moderate to Severe Papulopustular Rosacea
NCT03079531Phase 2Completed
- Start
- Jun 2017
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in papulopustular rosacea. Primary endpoint: Change From Baseline in Papule/Pustule Count at 16 weeks. Started Jun 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT03079531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079531.